Intercept Pharma (ICPT) Misses Q4 EPS Views
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/22/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
Wedbush Cuts PT on Intercept Pharma (ICPT) to $423, Remains Bullish
February 24, 2016 8:17 AM ESTWedbush analyst, Liana Moussatos, reiterated her Outperform rating on shares of Intercept Pharma (NASDAQ: ICPT) and thinks there will be a buying opportunity ahead of the release of AdComm briefing documents on April 7th. Acquisition value drops to $423 from $493 as expectations for the NASH launch are pushed to late19 from H1:18.
Intercept reported Q4 / FY revenues of $0.45MM / $2.78MM on GAAP EPS of $(3.62) / $(9.56) vs. consensus revenues est. of... More
